

Eiichi Araki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4341974/publications.pdf>

Version: 2024-02-01

121
papers

10,399
citations

87888

38
h-index

32842

100
g-index

134
all docs

134
docs citations

134
times ranked

9475
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice, 1995, 28, 103-117.	2.8	2,814
2	Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation, 2010, 1, 212-228.	2.4	1,206
3	International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Journal of Diabetes Investigation, 2012, 3, 39-40.	2.4	731
4	Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetology International, 2010, 1, 2-20.	1.4	322
5	Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 2020, 11, 165-223.	1.4	266
6	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology, 2017, 5, 951-964.	11.4	228
7	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2291-2301.	3.6	225
8	Japanese Clinical Practice Guideline for Diabetes 2016. Diabetology International, 2018, 9, 1-45.	1.4	215
9	Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes, 2006, 55, 120-7.	0.6	215
10	Statins Activate Peroxisome Proliferator-Activated Receptor γ Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase-Dependent Cyclooxygenase-2 Expression in Macrophages. Circulation Research, 2007, 100, 1442-1451.	4.5	214
11	International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetology International, 2012, 3, 8-10.	1.4	202
12	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the T1D-EdD Study). Diabetes Care, 2016, 39, 190-196.	8.6	190
13	Evaluation of Urinary 8-Hydroxydeoxy-Guanosine as a Novel Biomarker of Macrovascular Complications in Type 2 Diabetes. Diabetes Care, 2003, 26, 1507-1512.	8.6	173
14	SIRT7 Controls Hepatic Lipid Metabolism by Regulating the Ubiquitin-Proteasome Pathway. Cell Metabolism, 2014, 19, 712-721.	16.2	173
15	Impact of Endoplasmic Reticulum Stress Pathway on Pancreatic β -Cells and Diabetes Mellitus. Experimental Biology and Medicine, 2003, 228, 1213-1217.	2.4	161
16	Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation, 2020, 11, 1020-1076.	2.4	159
17	Japanese Clinical Practice Guideline for Diabetes 2016. Journal of Diabetes Investigation, 2018, 9, 657-697.	2.4	158
18	Effects of K-877, a novel selective PPAR α modulator (SPPARM α), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016, 249, 36-43.	0.8	146

#	ARTICLE	IF	CITATIONS
19	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , 2019, 42, 2262-2271.	8.6	146
20	Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 173-184.	1.5	127
21	Effects of Pemafibrate, a Novel Selective PPAR α Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. <i>Diabetes Care</i> , 2018, 41, 538-546.	8.6	122
22	Oxidative stress: A cause and therapeutic target of diabetic complications. <i>Journal of Diabetes Investigation</i> , 2010, 1, 90-96.	2.4	109
23	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARM α), in combination with statin treatment: Two randomized, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. <i>Atherosclerosis</i> , 2017, 261, 144-152.	0.8	101
24	Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 521-538.	2.0	97
25	Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: Report of the Committee on Causes of Death in Diabetes Mellitus. <i>Journal of Diabetes Investigation</i> , 2017, 8, 397-410.	2.4	95
26	Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. <i>Diabetes Research and Clinical Practice</i> , 2000, 48, 201-210.	2.8	91
27	Hyperglycemia Induces Cellular Hypoxia through Production of Mitochondrial ROS Followed by Suppression of Aquaporin-1. <i>PLoS ONE</i> , 2016, 11, e0158619.	2.5	85
28	Enhanced expression of PDX-1 and Ngn3 by exendin-4 during β^2 cell regeneration in STZ-treated mice. <i>Biochemical and Biophysical Research Communications</i> , 2005, 327, 1170-1178.	2.1	84
29	TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2009, 379, 43-48.	2.1	74
30	Mild Electrical Stimulation with Heat Shock Ameliorates Insulin Resistance via Enhanced Insulin Signaling. <i>PLoS ONE</i> , 2008, 3, e4068.	2.5	66
31	FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism. <i>Nature Communications</i> , 2019, 10, 1582.	12.8	57
32	Acetate alters expression of genes involved in beige adipogenesis in 3T3-L1 cells and obese KK-Ay mice. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2016, 59, 207-214.	1.4	53
33	Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor- α Modulator (SPPARM α), in Dyslipidemic Patients with Renal Impairment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 706.	4.1	53
34	Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of Committee on Causes of Death in Diabetes Mellitus. <i>Diabetology International</i> , 2017, 8, 117-136.	1.4	49
35	New glycemic targets for patients with diabetes from the Japan Diabetes Society. <i>Journal of Diabetes Investigation</i> , 2017, 8, 123-125.	2.4	48
36	Hyperthermia With Mild Electrical Stimulation Protects Pancreatic β^2 -Cells From Cell Stresses and Apoptosis. <i>Diabetes</i> , 2012, 61, 838-847.	0.6	43

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period. <i>Journal of Diabetes Investigation</i> , 2016, 7, 555-564.	2.4	42
38	Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. <i>Journal of Diabetes Investigation</i> , 2015, 6, 137-139.	2.4	41
39	Telmisartan Exerts Antiatherosclerotic Effects by Activating Peroxisome Proliferator-Activated Receptor- β in Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1268-1275.	2.4	40
40	Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the <sc>DEPICT</sc> study): 52-week results from a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1516-1526.	4.4	38
41	Identification of microRNA that represses IRS-1 expression in liver. <i>PLoS ONE</i> , 2018, 13, e0191553.	2.5	37
42	Nifedipine Induces Peroxisome Proliferator-Activated Receptor- β Activation in Macrophages and Suppresses the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1598-1605.	2.4	36
43	Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1267-1279.e4.	1.5	35
44	Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1737-1744.	4.4	35
45	Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bovine aortic endothelial cells. <i>Journal of Diabetes Investigation</i> , 2017, 8, 750-761.	2.4	33
46	Non-invasive measurement of skin autofluorescence to evaluate diabetic complications. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2016, 58, 135-140.	1.4	32
47	Effects of a novel selective peroxisome proliferator-activated receptor- α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1323-1332.	2.4	32
48	Efficacy and safety of dapagliflozin over 1-year as add-on to insulin therapy in <sc>Japanese</sc> patients with type 2 diabetes: the <sc>DAISY</sc> (Dapagliflozin Added to patients under InSulin) Tj ETQq0 0 0 4 BT / Overclock 10 Tf	4.4	32
49	Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2013, 12, 160.	6.8	27
50	Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARM α): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5537.	4.1	27
51	Mild Electrical Stimulation Increases Ubiquitinated Proteins and Hsp72 in A549 Cells via Attenuation of Proteasomal Degradation. <i>Journal of Pharmacological Sciences</i> , 2008, 108, 222-226.	2.5	25
52	An acyclic polyisoprenoid derivative, geranylgeranylacetone protects against visceral adiposity and insulin resistance in high-fat-fed mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E764-E771.	3.5	25
53	Statins mediate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor- β activation. <i>Biochemical and Biophysical Research Communications</i> , 2015, 457, 23-30.	2.1	24
54	Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials. <i>EBioMedicine</i> , 2014, 1, 80-89.	6.1	22

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 540-548.	4.4	22
56	Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 549-560.	4.4	21
57	Brown adipocyte-derived exosomal miR-132-3p suppress hepatic Srebf1 expression and thereby attenuate expression of lipogenic genes. <i>Biochemical and Biophysical Research Communications</i> , 2020, 530, 500-507.	2.1	20
58	Insulin receptor activation through its accumulation in lipid rafts by mild electrical stress. <i>Journal of Cellular Physiology</i> , 2013, 228, 439-446.	4.1	19
59	A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study). <i>Journal of Diabetes Investigation</i> , 2016, 7, 703-710.	2.4	19
60	Impaired balance is related to the progression of diabetic complications in both young and older adults. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1275-1282.	2.3	19
61	Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13-p12 in Japanese. <i>Journal of Human Genetics</i> , 2004, 49, 629-634.	2.3	18
62	Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 876-882.	4.4	18
63	Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. <i>Cardiovascular Diabetology</i> , 2021, 20, 96.	6.8	16
64	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes: A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. <i>Circulation Journal</i> , 2020, 85, 82-125.	1.6	16
65	Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2674-2683.	4.4	15
66	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001787.	2.8	15
67	Heat shock treatment with mild electrical stimulation safely reduced inflammatory markers in healthy male subjects. <i>Obesity Research and Clinical Practice</i> , 2010, 4, e101-e109.	1.8	14
68	Hypoglycemia Induces Mitochondrial Reactive Oxygen Species Production Through Increased Fatty Acid Oxidation and Promotes Retinal Vascular Permeability in Diabetic Mice. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1245-1259.	5.4	14
69	Troglitazone inhibits oxidized low-density lipoprotein-induced macrophage proliferation: Impact of the suppression of nuclear translocation of ERK1/2. <i>Atherosclerosis</i> , 2007, 191, 22-32.	0.8	13
70	Mild Electrical Stimulation Increases Stress Resistance and Suppresses Fat Accumulation via Activation of LKB1-AMPK Signaling Pathway in <i>C. elegans</i> . <i>PLoS ONE</i> , 2014, 9, e114690.	2.5	13
71	Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2012, 3, 179-184.	2.4	12
72	Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPAR γ . <i>Atherosclerosis</i> , 2019, 286, 30-39.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Impact of hepatic HSP72 on insulin signaling. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E305-E318.	3.5	12
74	Impacts of the 2016 Kumamoto Earthquake on glycemic control in patients with diabetes. Journal of Diabetes Investigation, 2019, 10, 521-530.	2.4	11
75	Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial. Scientific Reports, 2016, 6, 35690.	3.3	10
76	Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study. Endocrine Journal, 2019, 66, 745-752.	1.6	10
77	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPAR α Modulator, Pemafibrate. Journal of Atherosclerosis and Thrombosis, 2021, 28, 974-996.	2.0	10
78	Mechanism-based antioxidant therapies promise to prevent diabetic complications?. Journal of Diabetes Investigation, 2013, 4, 105-107.	2.4	9
79	Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions. Biochemical and Biophysical Research Communications, 2020, 524, 8-15.	2.1	9
80	The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 1279-1282.	4.4	8
81	The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report. BMC Endocrine Disorders, 2018, 18, 4.	2.2	8
82	A rare case showing subacute thyroiditis-like symptoms with amyloid goiter after anti-tumor necrosis factor therapy. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140117.	0.5	8
83	Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. Journal of Diabetes Investigation, 2014, 5, 320-326.	2.4	7
84	Baseline Plasma Aldosterone Level and Renin Activity Allowing Omission of Confirmatory Testing in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1990-e1998.	3.6	7
85	Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Diabetes, Obesity and Metabolism, 2021, 23, 2785-2794.	4.4	7
86	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Diabetology International, 2016, 7, 327-330.	1.4	6
87	Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus. Endocrine Journal, 2019, 66, 253-258.	1.6	6
88	Clinical Features of Patients With Acute Aortic Dissection After an Earthquake: Experience from the Kumamoto Earthquake 2016. American Journal of Hypertension, 2020, 33, 261-268.	2.0	6
89	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetology International, 2021, 12, 1-51.	1.4	6
90	Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1496-1504.	4.4	6

#	ARTICLE	IF	CITATIONS
91	Coexistence of resistance to thyroid hormone and papillary thyroid carcinoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 160003.	0.5	6
92	Clinical Features of Disaster-Associated Direct Deaths during Recent Inland Earthquakes in Japan. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 251, 169-173.	1.2	5
93	New classification and diagnostic criteria for insulin resistance syndrome. <i>Endocrine Journal</i> , 2022, 69, 107-113.	1.6	5
94	New classification and diagnostic criteria for insulin resistance syndrome. <i>Diabetology International</i> , 2022, 13, 337-343.	1.4	5
95	Predictors of coronary heart disease in Japanese patients with type 2 diabetes: Screening for coronary artery stenosis using multidetector computed tomography. <i>Journal of Diabetes Investigation</i> , 2010, 1, 50-55.	2.4	4
96	Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy. <i>Diabetes Therapy</i> , 2019, 10, 1347-1356.	2.5	4
97	Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets. <i>Journal of Clinical Medicine</i> , 2019, 8, 674.	2.4	4
98	Impact of tissue macrophage proliferation on peripheral and systemic insulin resistance in obese mice with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001578.	2.8	4
99	A homogeneous assay to determine high-density lipoprotein subclass cholesterol in serum. <i>Analytical Biochemistry</i> , 2021, 613, 114019.	2.4	4
100	Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma. <i>Journal of Diabetes Investigation</i> , 2021, 12, 668-671.	2.4	3
101	Clinical profiles of hyperglycemic crises: A single-center retrospective study from Japan. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1359-1366.	2.4	3
102	Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases. <i>Endocrine Connections</i> , 2021, 10, 521-533.	1.9	3
103	Atypical pituitary abscess lacking rim enhancement and diffusion restriction with an unusual organism, <i>Moraxella catarrhalis</i> : A case report and review of the literature. , 2021, 12, 617.		3
104	Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor β is a potential target for diabetic macrovascular complications. <i>Journal of Diabetes Investigation</i> , 2012, 3, 11-23.	2.4	2
105	Factors Affecting Human Damage in Heavy Rains and Typhoon Disasters. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 256, 175-185.	1.2	2
106	Dietary intake and physical activity in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 8). <i>Diabetology International</i> , 2022, 13, 344-357.	1.4	2
107	The PREDICTIVETM Study: a multinational, prospective observational study to evaluate the safety and efficacy of insulin detemir treatment in patients with type 1 and 2 diabetes—data from the Japan cohort. <i>Diabetology International</i> , 2012, 3, 11-20.	1.4	1
108	Evaluation of a new device for measurement of hemoglobin A1c for Japanese subjects. <i>Diabetology International</i> , 2013, 4, 112-116.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Efficacy of Pemafibrate on Atherogenic Dyslipidemia: Results of a Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Compared with Placebo. <i>Atherosclerosis Supplements</i> , 2018, 32, 25-26.	1.2	1
110	A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance without Hyperthyroidism. <i>World Neurosurgery</i> , 2018, 119, 394-399.	1.3	1
111	Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications from the Japan Diabetes Outcome Intervention Trial 3. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1022-1024.	2.4	1
112	with Diabetes. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 419-426.	0.0	1
113	HbA _{1c} : The lower the better?. <i>Journal of Diabetes Investigation</i> , 2011, 2, 45-47.	2.4	0
114	Cellular stress response pathways and diabetes mellitus. <i>Diabetology International</i> , 2015, 6, 239-242.	1.4	0
115	Mild electrical stimulation with heat shock attenuates renal pathology in adriamycin-induced nephrotic syndrome mouse model. <i>Scientific Reports</i> , 2020, 10, 18719.	3.3	0
116	New perspectives on insulin therapy. <i>Journal of Diabetes Investigation</i> , 2020, 11, 795-797.	2.4	0
117	The Amount of Residual Incretin Regulates the Pancreatic β -cell Function and Glucose Homeostasis. <i>Internal Medicine</i> , 2021, 60, 1433-1442.	0.7	0
118	Abstract 12384: Novel Approach to Residual Risk, K-877, a Potent and Selective PPAR- δ Modulator (SPPARM δ), Added-on to Pitavastatin in Japanese Patients With Dyslipidemia. <i>Circulation</i> , 2015, 132, .	1.6	0
119	8. Recent Advances in the Treatment of Diabetes. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 1865-1873.	0.0	0
120	ç³—â°¿ç—...è°¿ç™,ã,¬ã,ãf%ãf ©ã,ãf³2019. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 945-950.	0.0	0
121	Questionnaire Survey Regarding Troubles and Concerns Related to Clinical Research Based on the Clinical Trial Act for Clinicians and Academics. <i>Kurume Medical Journal</i> , 2021, , .	0.1	0